Daiichi Sankyo (OTCMKTS:DSNKY) Stock Dropped to “Strong Sell” by Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

Separately, Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 0.1%

Shares of Daiichi Sankyo stock opened at $17.90 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The company has a market cap of $33.35 billion, a P/E ratio of 20.81, a PEG ratio of 1.91 and a beta of -0.11. The firm’s 50 day moving average price is $17.79 and its 200-day moving average price is $17.16. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, sell-side analysts predict that Daiichi Sankyo will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.